Project Grant R01DK148765
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Miami $2,962,847 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to dissect the cellular dynamics and mechanisms of human pancreatic beta-cell regeneration using a novel in vivo model. The recipient will leverage an innovative transplantation system in which human pancreatic tissue slices and progenitor cells are engrafted into the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Vanderbilt University $140,396 on December 13, 2025, for research investigating the role of PDX1 C-terminal interaction domains during pancreatic endocrine differentiation and proliferation under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research examines how the homeobox transcription factor PDX1 regulates insulin-producing beta cell development and proliferation in the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Cincinnati Children's Hospital Medical Center $824,078 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to characterize drug-induced pancreatic injury using integrated computational, real-world evidence, and systems pharmacology approaches. The research project will employ computational methods to analyze pancreatitis transcriptomic signatures and perturbagen...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Brigham & Women's Hospital Inc. $730,898 on July 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate NR5A2 regulatory mechanisms in pancreas health and disease. The research examines how the transcription factor NR5A2 governs acinar cell identity and its role in preventing acinar-to-ductal metaplasia, a reversible process occurring during acute...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Chicago $197,600 on September 30, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the regulation of exocrine pancreatic innate immunity via microbially induced interleukin-22 (IL-22). The research establishes the role of gut microbes in modulating pancreatic IL-22 and the consequences of the gut-to-pancreas axis on pancreatic health...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Vanderbilt University $780,890 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how tuft cells resolve pancreatic injury through type 2 immune signaling in chronic pancreatitis. The research examines the role of chemosensory tuft cells that form during acinar-to-ductal metaplasia in chronic pancreatitis. The study tests the hypothesis...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $178,000 to Beckman Research Institute of The City of Hope on May 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how the native pancreatic microenvironment regulates human islet cell function in health and type 1 diabetes. The research employs human pancreatic tissue slices to preserve native cellular architecture and directly compares hormone...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Vanderbilt University Medical Center $175,000 on May 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct spatial profiling of pancreatic N-glycosylation in type 1 diabetes. The research employs state-of-the-art imaging technologies to map how protein N-glycosylation—the enzymatic attachment of complex carbohydrate chains to asparagine residues on...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Northwestern University $747,256 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to define the role of lymphatics in pancreatitis pathogenesis. The recipient will conduct research using mouse models, single-cell RNA sequencing, advanced imaging, and bioinformatics analyses to define functional roles of lymphatics in both acute and chronic pancreatitis...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Research Institute at Nationwide Children's Hospital $822,172 on July 6, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a randomized, double-blinded, placebo-controlled clinical trial testing whether pancreatic enzyme replacement therapy reduces the frequency of acute pancreatitis episodes in children with pancreatic sufficient acute recurrent and...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Alabama at Birmingham $718,880 on August 10, 2026, to investigate pancreatic regeneration in conditions caused by genetic mutation under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research develops and utilizes a novel animal model that mimics pancreatic injury and healing in individuals with cystic fibrosis caused by a specific CF gene mutation. The model enables researchers to toggle the disease state on and off, allowing study of how both the insulin-producing and digestive (enzyme-secreting) portions of the pancreas recover following damage. The project explores age-dependent differences in healing between young and adult animals, investigates cellular transdifferentiation during repair, and examines whether recovery in one pancreatic compartment supports healing in the other. This work addresses a gap in understanding pediatric pancreatic regeneration and recovery in genetic conditions, as prior research has focused predominantly on adult subjects and insulin-secreting tissue. Performance occurs in Birmingham, Alabama. The project runs from August 10, 2026, through June 30, 2030. The assistance type is a Project Grant.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $718.9k | 8/7/26 |